OTIC - Otonomy, Inc.
| Previous Close | 2.5200 |
| Open | 2.5600 |
| Bid | 2.4700 x 1800 |
| Ask | 2.5500 x 1400 |
| Day's Range | 2.4900 - 2.5700 |
| 52 Week Range | 1.5000 - 3.1550 |
| Volume | 65,089 |
| Avg. Volume | 75,696 |
| Market Cap | 76.875M |
| Beta (3Y Monthly) | 2.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5180 |
| Earnings Date | Nov 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.00 |
- Zacks
Top Ranked Momentum Stocks to Buy for December 3rd
Top Ranked Momentum Stocks to Buy for December 3rd
- GlobeNewswire
Otonomy to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Nov. 26, 2019 -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
- Thomson Reuters StreetEvents
Edited Transcript of OTIC earnings conference call or presentation 5-Nov-19 9:30pm GMT
Q3 2019 Otonomy Inc Earnings Call
- Zacks
Otonomy (OTIC) Reports Q3 Loss, Lags Revenue Estimates
Otonomy (OTIC) delivered earnings and revenue surprises of 26.67% and -59.68%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Otonomy Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s diseaseBroadest pipeline in neurotology field expanded to include gene.
- GlobeNewswire
Otonomy to Report Third Quarter 2019 Financial Results and Provide Corporate Update
SAN DIEGO, Oct. 29, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
- Simply Wall St.
What Kind Of Investor Owns Most Of Otonomy, Inc. (NASDAQ:OTIC)?
Every investor in Otonomy, Inc. (NASDAQ:OTIC) should be aware of the most powerful shareholder groups. Institutions...
- Zacks
Analysts Estimate Otonomy (OTIC) to Report a Decline in Earnings: What to Look Out for
Otonomy (OTIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss
GAINESVILLE, Fla. and CAMBRIDGE, Mass. and SAN DIEGO, Oct. 01, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human.
- GlobeNewswire
Otonomy to Present at the Cantor Global Healthcare Conference
SAN DIEGO, Sept. 26, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
- GlobeNewswire
Otonomy Initiating Phase 1/2 Clinical Trial of OTO-413 in Hearing Loss
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase 1/2 clinical trial of OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF), in patients with hearing loss. “Recent scientific research in the neurotology field has demonstrated that damage or loss of synaptic connections between inner ear hair cells and spiral ganglion neurons, known as cochlear synaptopathy, is involved in the hearing difficulty that many people experience in a loud environment, and that this pathology may also play a role in age-related and noise-induced hearing loss,” said Andrea Vambutas, M.D., Director for the Center of Hearing & Balance at the New York Head & Neck Institute.
- Thomson Reuters StreetEvents
Edited Transcript of OTIC earnings conference call or presentation 1-Aug-19 8:30pm GMT
Q2 2019 Otonomy Inc Earnings Call
- GlobeNewswire
Otonomy Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Clinical-stage programs on track with results expected from three trials in 2020Current capital funds operations into 2021 Conference call and webcast today at 4:30 p.m. EDT.
- GlobeNewswire
Otonomy to Report Second Quarter 2019 Financial Results and Provide Corporate Update
SAN DIEGO, July 25, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
- Simply Wall St.
Why Otonomy, Inc. (NASDAQ:OTIC) Is An Attractive Investment To Consider
As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I...
- GlobeNewswire
Otonomy to Present at the Raymond James Life Sciences and MedTech Conference
SAN DIEGO, June 12, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
- Thomson Reuters StreetEvents
Edited Transcript of OTIC earnings conference call or presentation 6-May-19 8:30pm GMT
Q1 2019 Otonomy Inc Earnings Call
- Zacks
Otonomy (OTIC) Reports Q1 Loss, Misses Revenue Estimates
Otonomy (OTIC) delivered earnings and revenue surprises of 15.22% and -40.92%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Otonomy: 1Q Earnings Snapshot
The San Diego-based company said it had a loss of 39 cents per share. The biotechnology company posted revenue of $192,000 in the period. In the final minutes of trading on Monday, the company's shares ...
- GlobeNewswire
Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update
OTO-313 Phase 1/2 trial in tinnitus initiated; results expected in first half of 2020OTIPRIO® co-promotion agreement completed with Glenmark TherapeuticsOTIVIDEX™ Phase 3 trial.
- ACCESSWIRE
Otonomy, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 6, 2019 / Otonomy, Inc. (NASDAQ: OTIC ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 6, 2019 at 4:30 PM Eastern Time. ...
- PR Newswire
Glenmark Therapeutics Expands Specialty Portfolio with OTIPRIO® Co-Promotion Agreement in the U.S. with Otonomy for Acute Otitis Externa Indication
MAHWAH, N.J., May 2, 2019 /PRNewswire/ -- Glenmark Therapeutics Inc., USA, a wholly-owned subsidiary of Glenmark Holding SA., today announced a co-promotion agreement with Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. Glenmark Therapeutics is dedicated to developing and commercializing a franchise of branded products for Glenmark Pharmaceuticals and is focused in the areas of respiratory and dermatology. Ryaltris™ (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg]), formerly GSP 301 Nasal Spray, is the company's leading respiratory pipeline asset and currently under review with the U.S. Food and Drug Administration (FDA) as a treatment for seasonal allergic rhinitis in patients 12 years and older.
- GlobeNewswire
Otonomy Announces OTIPRIO® Co-Promotion Agreement with Glenmark Therapeutics for Acute Otitis Externa Indication
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the signing of a co-promotion agreement with Glenmark Therapeutics Inc., USA, a wholly-owned subsidiary of Glenmark Holding SA., which is dedicated to building and commercializing a franchise of branded products for Glenmark Pharmaceuticals focused in the areas of respiratory and dermatology. This agreement provides Glenmark Therapeutics with an exclusive right to promote OTIPRIO (ciprofloxacin otic suspension) to ear, nose and throat (ENT) physician offices in the United States and its territories for the treatment of acute otitis externa (AOE) in patients 6 months of age and older due to Pseudomonas aeruginosa and Staphylococcus aureus.
- GlobeNewswire
Otonomy to Participate in SunTrust Robinson Humphrey Life Sciences Summit
SAN DIEGO, May 01, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
- GlobeNewswire
Otonomy to Report First Quarter 2019 Financial Results and Provide Corporate Update
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the first quarter 2019 as well as provide a corporate update at 4:30 p.m. EDT on May 6, 2019. The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 8076448. A live webcast of the call will be available online in the investor relations section of Otonomy’s website at www.otonomy.com and will be archived there for 30 days.
